This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GSK or NVO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GSK vs. NVO: Which Stock Is the Better Value Option?
3 Big Pharma Outperformers to Watch Out For in the Near Term
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
Top Research Reports for Adobe, Novo Nordisk & Qualcomm
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Adobe (ADBE), Novo Nordisk (NVO), and Qualcomm (QCOM).
Ascendis (ASND) Gets Positive CHMP Opinion for GHD Drug Filing
by Zacks Equity Research
Ascendis Pharma (ASND) is seeking approval for TransCon hGH for the treatment of pediatric growth hormone deficiency in Europe.
Novo Nordisk (NVO) Gets Positive CHMP Opinion for Wegovy
by Zacks Equity Research
The CHMP gives a positive opinion on, and recommends approval to Novo Nordisk's (NVO) Wegovy for chronic weight management in adults with obesity.
Prothena (PRTA) Q3 Earnings Miss, Pipeline Progress in Focus
by Zacks Equity Research
Prothena misses on earnings and revenues in the third quarter of 2021. Nevertheless, the company's progress with its AD pipeline is encouraging.
Intercept (ICPT) Beats on Q3 Earnings & Sales, Ups View
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in the third quarter and sales beat estimates.
Novo Nordisk's (NVO) Q3 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected results for Q3. Sales are aided by growth in Diabetes and Obesity Care owing to higher GLP-1 revenues.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Top Stock Reports for Alphabet, Netflix & Thermo Fisher
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Netflix, Inc. (NFLX), and Thermo Fisher Scientific Inc. (TMO).
Regeneron (REGN) Dupixent Gets FDA Nod for Asthma in Children
by Zacks Equity Research
Regeneron (REGN) and Sanofi's (SNY) Dupixent secures FDA approval to treat children aged 6-11 years with moderate to severe asthma.
GSK or NVO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GSK vs. NVO: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Pfizer, Novo Nordisk and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Novo Nordisk and Sanofi
AstraZeneca (AZN) to Buy Full Stake in Rare Disease Drugmaker
by Zacks Equity Research
AstraZeneca (AZN) looks to buy full stake in Caelum Biosciences to sharpen its focus on rare-disease drugs.
3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health
by Kinjel Shah
Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.
Lilly's (LLY) Erbitux Gets FDA Nod for Expanded Use in CRC
by Zacks Equity Research
Eli Lilly (LLY) secures FDA approval for Erbitux combined with Pfizer's Braftovi to treat BRAF V600E mutation-positive metastatic CRC in adult patients who received prior therapy.
PFE vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
OPKO (OPK) BLA Review for Growth Hormone Deficiency Drug Delayed
by Zacks Equity Research
The FDA extends the PDUFA action date for OPKO (OPK)/Pfizer's BLA for somatrogon to treat pediatric patients with growth hormone deficiency. The review period has been further extended by three months.
Looking for a Growth Stock? 3 Reasons Why Novo Nordisk (NVO) is a Solid Choice
by Zacks Equity Research
Novo Nordisk (NVO) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why Novo Nordisk (NVO) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Ascendis (ASND) Rallies on First FDA-Approved Drug Skytrofa
by Zacks Equity Research
Ascendis' (ASND) Skytrofa gets FDA approval for treating growth failure in pediatric patients. The drug is also the first FDA-approved product in the company's portfolio.
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On (Revised)
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here is Why Prothena (PRTA) is Up More Than 155% in Three Months
by Zacks Equity Research
Prothena (PRTA) surges substantially in the past three months on solid prospects of its AD candidates following Biogen???s AD drug approval.